These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 25602299)

  • 1. Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular morbidity over 10years in the CLARICOR randomised, blinded clinical trial.
    Winkel P; Hilden J; Hansen JF; Kastrup J; Kolmos HJ; Kjøller E; Jensen GB; Skoog M; Lindschou J; Gluud C;
    Int J Cardiol; 2015 Mar; 182():459-65. PubMed ID: 25602299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease.
    Jensen GB; Hilden J; Als-Nielsen B; Damgaard M; Hansen JF; Hansen S; Helø OH; Hildebrandt P; Kastrup J; Kolmos HJ; Kjøller E; Lind I; Nielsen H; Petersen L; Jespersen CM; Gluud C;
    J Cardiovasc Pharmacol; 2010 Feb; 55(2):123-8. PubMed ID: 19920766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease.
    Gluud C; Als-Nielsen B; Damgaard M; Fischer Hansen J; Hansen S; Helø OH; Hildebrandt P; Hilden J; Jensen GB; Kastrup J; Kolmos HJ; Kjøller E; Lind I; Nielsen H; Petersen L; Jespersen CM;
    Cardiology; 2008; 111(4):280-7. PubMed ID: 18451646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial.
    Jespersen CM; Als-Nielsen B; Damgaard M; Hansen JF; Hansen S; Helø OH; Hildebrandt P; Hilden J; Jensen GB; Kastrup J; Kolmos HJ; Kjøller E; Lind I; Nielsen H; Petersen L; Gluud C;
    BMJ; 2006 Jan; 332(7532):22-7. PubMed ID: 16339220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 10-Year Associations Between Tumor Necrosis Factor Receptors 1 and 2 and Cardiovascular Events in Patients With Stable Coronary Heart Disease: A CLARICOR (Effect of Clarithromycin on Mortality and Morbidity in Patients With Ischemic Heart Disease) Trial Substudy.
    Carlsson AC; Ruge T; Kjøller E; Hilden J; Kolmos HJ; Sajadieh A; Kastrup J; Jensen GB; Larsson A; Nowak C; Jakobsen JC; Winkel P; Gluud C; Ärnlöv J
    J Am Heart Assoc; 2018 Apr; 7(9):. PubMed ID: 29686027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Compliance with and short-term adverse events from clarithromycin versus placebo in patients with stable coronary heart disease: the CLARICOR trial.
    Jespersen CM; Kolmos HJ; Frydendall N; Hilden J; Gluud C; Hansen JF;
    J Antimicrob Chemother; 2009 Aug; 64(2):411-5. PubMed ID: 19477891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective?
    Winkel P; Hilden J; Fischer Hansen J; Hildebrandt P; Kastrup J; Kolmos HJ; Kjøller E; Jespersen CM; Gluud C; Jensen GB;
    Cardiology; 2011; 118(1):63-7. PubMed ID: 21447948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cathepsin B and S as markers for cardiovascular risk and all-cause mortality in patients with stable coronary heart disease during 10 years: a CLARICOR trial sub-study.
    Wuopio J; Hilden J; Bring C; Kastrup J; Sajadieh A; Jensen GB; Kjøller E; Kolmos HJ; Larsson A; Jakobsen JC; Winkel P; Gluud C; Carlsson AC; Ärnlöv J
    Atherosclerosis; 2018 Nov; 278():97-102. PubMed ID: 30261474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteoprotegerin independently predicts mortality in patients with stable coronary artery disease: the CLARICOR trial.
    Bjerre M; Hilden J; Kastrup J; Skoog M; Hansen JF; Kolmos HJ; Jensen GB; Kjøller E; Winkel P; Flyvbjerg A; Gluud C;
    Scand J Clin Lab Invest; 2014 Nov; 74(8):657-64. PubMed ID: 25026506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating endostatin as a risk factor for cardiovascular events in patients with stable coronary heart disease: A CLARICOR trial sub-study.
    Ruge T; Carlsson AC; Kjøller E; Hilden J; Kolmos HJ; Sajadieh A; Kastrup J; Jensen GB; Larsson A; Nowak C; Jakobsen JC; Winkel P; Gluud C; Ärnlöv J
    Atherosclerosis; 2019 May; 284():202-208. PubMed ID: 30959314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors for major cardiovascular outcomes in stable ischaemic heart disease (PREMAC): statistical analysis plan for data originating from the CLARICOR (clarithromycin for patients with stable coronary heart disease) trial.
    Winkel P; Jakobsen JC; Hilden J; Lange T; Jensen GB; Kjøller E; Sajadieh A; Kastrup J; Kolmos HJ; Larsson A; Ärnlöv J; Gluud C
    Diagn Progn Res; 2017; 1():10. PubMed ID: 31093541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) and the risk of vascular morbidity and mortality in patients with coronary artery disease.
    Lafeber M; Spiering W; van der Graaf Y; Nathoe H; Bots ML; Grobbee DE; Visseren FL
    Am Heart J; 2013 Aug; 166(2):282-289.e1. PubMed ID: 23895811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Intervention with clarithromycin in patients with stable coronary heart disease--the CLARICOR trial: secondary publication].
    CLARICOR-Gruppen
    Ugeskr Laeger; 2007 Feb; 169(6):497-9. PubMed ID: 17303029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies.
    Schembri S; Williamson PA; Short PM; Singanayagam A; Akram A; Taylor J; Singanayagam A; Hill AT; Chalmers JD
    BMJ; 2013 Mar; 346():f1235. PubMed ID: 23525864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
    Fox K; Ferrari R; Tendera M; Steg PG; Ford I;
    Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Visit-to-visit low-density lipoprotein cholesterol variability and risk of cardiovascular outcomes: insights from the TNT trial.
    Bangalore S; Breazna A; DeMicco DA; Wun CC; Messerli FH;
    J Am Coll Cardiol; 2015 Apr; 65(15):1539-48. PubMed ID: 25881936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three-year follow-up in a subset of high-risk patients randomly assigned to off-pump versus on-pump coronary artery bypass surgery: the Best Bypass Surgery trial.
    Møller CH; Perko MJ; Lund JT; Andersen LW; Kelbæk H; Madsen JK; Winkel P; Gluud C; Steinbrüchel DA
    Heart; 2011 Jun; 97(11):907-13. PubMed ID: 21415073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR trial.
    Harutyunyan MJ; Mathiasen AB; Winkel P; Gøtze JP; Hansen JF; Hildebrandt P; Jensen GB; Hilden J; Jespersen CM; Kjøller E; Kolmos HJ; Gluud C; Kastrup J;
    Scand J Clin Lab Invest; 2011 Feb; 71(1):52-62. PubMed ID: 21108561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clarithromycin use and risk of death in patients with ischemic heart disease.
    Andersen SS; Hansen ML; Norgaard ML; Folke F; Fosbøl EL; Abildstrøm SZ; Raunsø J; Madsen M; Køber L; Gislason GH; Torp-Pedersen C
    Cardiology; 2010; 116(2):89-97. PubMed ID: 20523043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
    Keech A; Simes RJ; Barter P; Best J; Scott R; Taskinen MR; Forder P; Pillai A; Davis T; Glasziou P; Drury P; Kesäniemi YA; Sullivan D; Hunt D; Colman P; d'Emden M; Whiting M; Ehnholm C; Laakso M;
    Lancet; 2005 Nov; 366(9500):1849-61. PubMed ID: 16310551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.